Why Hims & Hers Health (HIMS) is on investors’ radar

Hims & Hers Health (HIMS) has drawn fresh attention after a sharp 57% move over the past week. This has prompted investors to reassess how its recent share performance lines up with reported revenue and net income figures.

That sharp 57.4% 7 day share price return and 48.4% 30 day share price return come after a weaker patch, with the 90 day share price return at a 33.4% decline and year to date share price return at a 25.9% decline. The three year total shareholder return of around 1.5x suggests longer term holders have experienced a very large gain even after recent volatility.

If fast moving stocks like Hims & Hers Health have your attention, this could be a good moment to widen your search and check out 18 top founder-led companies.

With Hims & Hers trading close to analysts’ targets while some models suggest a sizable intrinsic discount, you have to ask yourself: is this recent surge still leaving upside on the table, or is the market already pricing in future growth?

Most Popular Narrative: 71.2% Undervalued

Hims & Hers Health's most followed narrative, according to BlackGoat, points to a fair value of $86.09 versus the last close at $24.77, a wide gap that turns the recent price spike into just one part of a much bigger story.

Hims & Hers Health isn’t a telehealth gimmick or a GLP-1 hype stock. It is quietly becoming the top-of-funnel infrastructure layer for healthcare in the United States. It is executing a strategy similar to Amazon, Spotify, and Costco: deliver more value per dollar spent, reinvest scale advantages, and win via customer-centric efficiency.

Curious what kind of revenue trajectory, margin profile, and future profit multiple support that $86.09 fair value? The core assumptions here lean heavily on compound earnings growth and a business model that aims to scale like a platform, not a one-category telehealth brand. If you want to see which specific growth and profitability targets sit behind that gap to the current price, the full narrative lays it out step by step.

Result: Fair Value of $86.09 (UNDERVALUED)

However, you still need to weigh real pressure points, including tighter scrutiny of GLP-1 compounding and any future regulatory pushback on Hims & Hers’ telehealth prescribing model.

Another Angle on Valuation

The user narrative leans on growth and cash generation, but our numbers tell a tighter story on price. Hims & Hers trades on a P/E of 44x, which is roughly double the US Healthcare industry at 22.1x and well above a fair ratio of 20x, even if it sits below peer average at 51.6x. That kind of gap can either compress or stretch further. Where do you think the pendulum swings from here?

Next Steps

If this mix of optimism and caution around Hims & Hers resonates with you, take a closer look at the numbers yourself and decide quickly where you stand, then weigh up the balance of 3 key rewards and 3 important warning signs before you make your next move.

Looking for more investment ideas?

If Hims & Hers has sharpened your focus, do not stop here. Broaden your watchlist with a few focused stock lists built from clear, transparent criteria.

• Spot potential bargains quickly by scanning our 48 high quality undervalued stocks that pair quality fundamentals with prices some investors may be overlooking.
• Prioritise resilience first and see which companies pass our checks in the 68 resilient stocks with low risk scores so you are not caught off guard by hidden issues.
• Get ahead of the crowd by reviewing a screener containing 26 high quality undiscovered gems before other investors start paying attention to these names.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.